About: The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone
Creator	Lin, Sheng Liu, Can Chen, Ningdai Chen, Tianbin Fu, Ya Huang, Huanhuan Ou, Qishui Wu, Wennan Xun, Zhen Zeng, Yongbin
source	Medline; PMC
abstract	Background: There are limited data regarding the efficacy of addition of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) to Peg-IFNα-2b in HBeAg positive chronic hepatitis B (CHB) patients without early response to Peg-IFNα-2b. In this study, we aimed to evaluate the efficacy of ETV and TDF in HBeAg positive CHB patients who had a poor response to Peg-INFα-2b at the end of 12 weeks of monotherapy. Methods: A total of 40 HBeAg-positive CHB patients who were naive to antiviral therapy were recruited. The patients received a subcutaneous injection of Peg-IFNα-2b (180 µg) once a week for 12 weeks. However, the patients had a poor response to Peg-INFα-2b at the end of the 12-week-period monotherapy. The patients were then divided into two therapeutic protocol groups: (1) Group A: Patients received Peg-IFNα-2b (180 µg) subcutaneously weekly and ETV (0.5 mg) orally once daily for 48 weeks; (2) Group B: Patients received Peg-IFNα-2b (180 µg) subcutaneously weekly and TDF (300 mg) orally once daily for 48 weeks. The therapeutic efficacy was evaluated. Blood samples were collected at baseline and every 12 weeks. Routine biochemical tests including ALT, AST, etc. were measured by automated biochemical technique. HBV DNA was quantified using the TaqMan PCR assay. The levels of HBsAg, HBsAb, HBeAg, HBeAb and HBcAb were measured using a commercial chemiluminescent microparticle immunoassay. Results: The HBsAg level declined rapidly in both two treatment groups during the first 12 weeks and declined gradually in the next 36 weeks. At week 48, the mean ΔHBsAg level in Peg-IFNα-2b+TDF group was significantly higher than that in Peg-IFNα-2b +ETV group (-1.799 ± 0.3063 vs. -1.078 ± 0.2028, P=0.0491). The HBeAg loss rate was significantly higher in TDF add-on group than that in ETV add-on group at week 48 (40% vs. 10%, P=0.028). At week 48, the proportions of patients with undetectable HBV DNA (<500 IU/mL) were 80% (16 out of 20) and 95% (19 out of 20) in Peg-IFNα-2b+ETV group and Peg-IFNα-2b+TDF group, respectively. Conclusions: This real world study demonstrated that the efficacy of addition of TDF to Peg-IFNα-2b is superior to the efficacy of addition of ETV to Peg-IFNα-2b in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone. However, this present study also requires a larger sample size study to verify in the future.
has issue date	2020-06-08(xsd:dateTime)
bibo:doi	10.7150/ijms.45658
bibo:pmid	32624702
has license	cc-by
sha1sum (hex)	20fc0a8c2fad0d30e202de3a07c97bbbc6926576
schema:url	https://doi.org/10.7150/ijms.45658
resource representing a document's title	The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone
has PubMed Central identifier	PMC7330670
has PubMed identifier	32624702
schema:publication	Int J Med Sci
resource representing a document's body	covid:20fc0a8c2fad0d30e202de3a07c97bbbc6926576#body_text
is schema:about of	named entity 'Group A' named entity 'patients' named entity 'weeks' named entity 'efficacy' named entity 'HBsAg' named entity 'loss' named entity 'patients' named entity 'response' named entity 'treatment groups' named entity 'patients' named entity 'CHB' named entity 'weeks' named entity 'limited' named entity 'biochemical' covid:arg/20fc0a8c2fad0d30e202de3a07c97bbbc6926576 named entity 'daily' named entity 'hepatitis B' named entity 'received' named entity 'higher' named entity 'TDF' named entity 'declined' named entity 'weeks' named entity 'automated' named entity 'antiviral therapy' named entity 'TDF group' named entity 'ALT' named entity 'Patients' named entity 'total' named entity '12 weeks' named entity 'HBeAg' named entity 'Blood samples' named entity 'CHB' named entity 'HBcAb' named entity 'biochemical' named entity 'chronic hepatitis' named entity 'AST' named entity 'TaqMan' named entity 'subcutaneously' named entity 'microparticle' named entity 'tenofovir disoproxil fumarate' named entity '12 weeks' named entity 'TDF' named entity 'Entecavir' named entity 'neutrophil' named entity 'Abbott Laboratories' named entity 'reverse transcription' named entity 'CHB' named entity 'TDF' named entity 'statistical significance' named entity 'antiviral' named entity 'HDV' named entity 'HBeAg' named entity 'covalently' named entity 'combination therapy' named entity 'Chinese Medical Association' named entity 'Chronic Hepatitis' named entity 'Kolmogorov-Smirnov test' named entity 'HBeAg' named entity 'serologic' named entity 'HBcAb' named entity '12 weeks' named entity 'biochemical' named entity 'serum' named entity '12 weeks' named entity 'probability' named entity 'genotype' named entity 'normal distribution' named entity 'HBeAg' named entity 'follow-up' named entity 'immunomodulatory' named entity 'sample size' named entity 'HBeAg'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software